It's a biotech, remember? Catalysts! Positive results on the OM, but also starting K p2 in Italy and US, starting p3 for ABSSSI will drive this thing. Bollinger band behavior is short term here with a void in pipeline information. TA is tempting, but knowing when it does not really apply to short-term growth is also part of the analysis as I am sure you know. My guess, based on the strong pre-clinicals as well as the confirmed ABSSSI drug action is that the OM trial will be impressive. That alone is enough to start the climb to double digits, etc.
It is easier to go Strong Buy here based on Brilacidin than the still early prospects for Kevetrin which will require a much longer P2. The nice thing about Brilacidin from a development standpoint, like painkillers or dermatitis treatments, definitive results are quick and clinical trials are relatively short.
While I think the earnings report will be very favorable, the new leadership and price runnup has set expectations high - and even a "decent" report might mean a temporary pullback. Who knows?
This little tech stock is a lot like trading in a small biotech, except we don't know everything in the pipeline.
VERY tempting to add in here. I am always amazed at the number of posters on every board who exhibit either sheer ignorance or are simply naive (to be kind) when it comes to believing these stupid articles. People profit-taking in here, concerned about a "flawed business model"? Have they ever actually reviewed or developed strategic plans, negotiated on the company's behalf in this industry, or have anything more than an MBA and desk job on which to assess these articles. Excuse me for being perhaps too critical of my fellow retail folks, but MIFI shows every indication of a "good" showing on the quarterly as well as medium term performance going forward - but I do not write SA or other articles (BTW, almost anyone can). Many are technically shallow and miss/omit key points to advance their position. IMO.
All of their announcements point to a good quarter. Financials and contract announcements will tell the story but this is an easy one. Downside risk is limited compared to their market position, market cap and potential upside. I added significantly early last week on the obvious profit-taking pull-back.